奥曲肽及其类似物用于肿瘤治疗的进展

马寄晓 ,  叶大铸

downloadPDF
文章导航 > 国际放射医学核医学杂志  > 2005,  29 > 2: (79-84)  
引用本文:
shu
Citation:
shu

奥曲肽及其类似物用于肿瘤治疗的进展

  • 1. 上海交通大学附属第六人民医院核医学科;

  • 2. Memorial Sloan-Kettering Cancer Center; New York 10021; USA

  • 中图分类号: R817.5

Advances in tumor treatment with labeled somatostatin analogues

  • 1. Department of Nuclear Medicine, Shanghai Sixth People's Hospital, Shanghai Jiao Tong Uiversity, Shanghai 200233, China;

  • 2. Memorial Sloan-Kettering Cancer Center, New York 10021, USA

  • CLC number: R817.5

  • 摘要: 简单综述90Y-奥曲肽、177Lu-奥曲肽在肿瘤治疗中的应用价值。对奥曲肽治疗的原理、在肿瘤及正常组织中的分布、对肾脏功能的影响和保护剂的应用进行介绍,主要治疗的病种包括不摄取131I的分化型甲状腺癌转移灶、Hurthle细胞甲状腺癌、甲状腺髓样癌、来自胃肠胰的神经内分泌肿瘤、小细胞癌、嗜铬细胞瘤等。对应用适合的剂量和未来新的可能用于临床治疗的放射肽和发展方向加以综述。
    Abstract: The values of 90Y-octreotide and 177Lu-octreotate in tumor treatment were briefly reviewed.The rationale of clinincal applications, the distribution of radiopeptide in tumor and nomal tissues and appli-cation of renal protective agents were reviewed as well. Tumor with potential therapeutic responses are many such as non-iodide avid cancer of thyroid gland, Hurthle cell thyroid cancer, medullary thyroid cancer, neuroendo-gastro-entero-pancreatic(GEP)tumor, small cell l cancer, carcinoid tumors and pheochromocytoma. The current state of clinical use of radiopeptide for therapy of tumors, the development of new compounds and future development, the dosage of radiopeptide for tumor treatment with well tolerated and remarkable clinical benefit were presented.
  • [1] Boerman O C, Oyen W J G, Corstens F H M. Between the scylla and charybdis of peptide radionuclide therapy:hitting the tumor and saving the kidney[J]. Eur J Nucl Med, 2001, 28:1447-1449.
    [2] Forssell-Aronsson E, Bernhardt P, Nilsson O, et al. Biodistribution data from 100 patients iv. injected with 111In-DTPA-D-pheloctreotide[J]. Acta Oncol, 2004, 43(5):436-442.
    [3] Bushnell D, Menda Y, O'Dorisio T, et al. Effect of intravenous amino acid administration with Y-90 DOTA-Phe1-Tyr3-octreotide (SMT487[Octreo TherTM])treatment[J]. Cancer Biother Radiopharm,2004, 19(1):35-41.
    [4] Pauwels S, Barone R, Walrand S, et al. Practical dosimetry of peptide receptor radionuclide therapy with 90Y-labeled somatostatin analogs[J]. J Nucl Med, 2005, 46(1 suppl):92S-98S.
    [5] Moll S, Nickeleit V, Mueller-Brand J, et al. A new cause of renal thrombotic microangiopathy:Yttrium-90-DOTATOC internal radiotherapy[J]. Am J kidney Dis, 2001,37(4):847-851.
    [6] Bodei L, Cremonesi M, Zoboli S, et al. Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion, a phase Ⅰ study[J]. Eur J Nucl Med Mol Imaging, 2003,30(2):207-216.
    [7] Rolleman EJ, Valkema R, de Jong M, et al. Safe and effective inhibition of renal uptake of radiolabelled octreotidc by a combination of lysine and arginine[J]. Eur J Nucl Med Mol Imaging, 2003, 30(1):9-15.
    [8] Barone R, Pauwels S, De Camps J, et al. Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analogs[J]. Nephrol Dial Transplant, 2004, 19(9):2275-2281.
    [9] Barone R, Borson-Chazot F, Valkema R, et al. Patient-specific dosimetry in predicting renal toxicity with 90Y-DOTATOC:relevence of kidney volume and dose rate in finding a dose-effect relationship[J]. J Nucl Med, 2005, 46(lsuppl):99s-106s.
    [10] Gabriel M, Froehlich F, Decristoforo C, et al. EDDA/HYNIC-TOC and 18F-FDG in thyroid cancer patients with negative 131I whole body scan[J]. Eur J Nucl Med Mol Imaging, 2004, 31(3):330-341.
    [11] Giammarile F, Houzard C, Bournaud C, et al. Diagnostic management of suspected metastatic thyroid carcinoma:clinical value of octreotide scintigraphy in patients with negative high-dose radioiodine Scans[J]. Eur J Endocrinol, 2004, 150(3):277-283.
    [12] Stokkel M P, Verkooijen R B, Smit J W. Indium-111 octretide scintigraphy for the detection of non-functioning metastases from differentiated thyroid cancer:diagnostic and prognostic value[J]. EurJ Nucl Med Mol Imaging, 2004, 31(7):950-957.
    [13] Stokkel MP, Rcigman HI, Verkooijen RB, et al. Indiun-111-octreotide scintigraphy in differentiated thyroid carcinoma metastases that do not respond to treatment with high-dose I- 131[J]. J Cancer Res Clin Oncol, 2003, 129(5):287-294.
    [14] Kostoglou-Athanassiou I, Pappas A, Gogou L, et al. Scintigraphy with 111In-octreotide and 201Tl in a Hurthle cell thyroid carcinoma without detectable radio-iodine uptake. Report of a case and review of the literature[J]. Horm Res, 2003, 60(4):205-208.
    [15] Tounissen J J, Kwekkeboom D J, Kooij P P, et al. Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid cancer[J]. J Nucl Med, 2005, 46(1 suppl):107s-114s.
    [16] Rufini V, Salvatori M, Garganese M C, et al. Role of nuclear medicine in the diagnosis and therapy of medullary thyroid carcinoma[J]. Rays,2000, 25(2):273-282.
    [17] Papotti M, Kumar U, Volante M, et al. Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid[J]. Clin Endocsinol, 2001, 54(5):641-649.
    [18] Bodei L, Haudkiewicz-Junak D, Grana C, et al. Receptor radionuclide therapy with 90Y-DOTATOC in patients with medullary thyroid carcinomas[J]. Cancer Biother Radiophasm, 2004, 19(1):65-71.
    [19] Behe M, Behr T M. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies[J]. Biopolymers, 2002, 66(6):399-418.
    [20] Vainas I, Koussis CH, Pazaitou-Panayiotou K, et al. Somatastatin receptor expression in vivo and response to somatostatin analog therapy with or without other antineoplastic treatments in advanced medulary thyroid carcinoma[J]. J Exp Clin Cancer Res, 2004, 23(4):549-559.
    [21] Saga T, Tamaki N, Itoi K, et al. Phase Ⅲ additional clinical study of 111In-pentetrootide (MP-1727):diagnosis of gastrointestinal hormone producing tumors based on the presence of somatostatin receptor[J].Kaku Iguku, 2003, 40(2):185-203.
    [22] Reubi JC. Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment[J]. Neuroendocrinology, 2004, 80(suppl 1):51-56.
    [23] Gibril F, Jensen R T. Diagnostic uses of radiolabelled somatostatin receptor analogues in gastroentero-pancreatic endocrine tumors[J].Dig Liver Dis, 2004, 36(suppl 1):S106-S120.
    [24] Virgolini I, Traub T, Novotny C, et al. Experience with indium-111and yttrium-90-1abeled somatostat in analogs[J]. Curr Pharm Des,2002, 8(20):1781-1807.
    [25] Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs[J]. J Nucl Med, 2005, 46:62S-66S.
    [26] Mundschenk J, Unger N, Schulz S, et al. Somatostatin receptor subtypes in human pheochromocytoma:subeellular expression pattern and functional relevance for octrootide scintigraphy[J]. J Clin Endocrin Metab, 2003, 88(11):5150-5157.
    [27] Pless M, Waldherr C, Maecke H, et al. Targeted radiotherapy for small cell lung cancer using 90Yttrium-DOTATOC, an Yttrium labelled somatostatin analogue:a pilot trial[J]. Lung Cancer, 2004,45(3):365-371.
    [28] Schmitt A, Bernhardt P, Nilsson O, et al. Radiation therapy of small cell lung cancer with 177Lu-DOTA-Tyr3-octreotate in an animal model[J]. J Nucl Med, 2004, 45(9):1542-1548.
    [29] Spieth ME, Lin YG, Nguyen TT. Diagnosing and treating small-cell carcinomas of prostatic origin[J]. Clin Nucl Med, 2002, 27(1):11-17.
    [30] Valkema R, Pauwels SA, Kvols LK, et al. Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0), Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate[J]. J Nucl Med, 2005, 46(Suppl 1):83S-91S.
    [31] Waldherr C, Pless M, Maecke H.R, et al. Tumor response and clinical benefit in neuroendocrin tumors after 7.4Bq 90Y-DOTATOC[J]. J Nucl Med, 2002, 43(5):610-616.
    [32] Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment of patients with gastro-entero-pancreatic(GEP) tumours with the novel radiolabelled somatostatin analogue[177Lu-DOTA(0),Tyrs]octreotate[J]. Eur J Nucl Med Mol Imaging, 2003, 30(3):417-422.
    [33] de Jong M, Breeman WA, Valkema R, et al. Combination radionuelide therapy using 177Lu- and 90Y-labeled somatostatin analogs[J]. J Nucl Med, 2005, 46(1 suppl):13S-17S.
    [34] Reubi JC, Macke HR, Krenning EP. Candidates for peptide receptor radiotherapy today and in the future[J]. J Nucl Med, 2005, 46(1 suppl):67S-75S.
    [35] Gotthardt M, Boermann OC, BehrTM, et al. Development and clinical application of peptide-based radiopharmaceuticals[J]. Curr Pharm Des, 2004, 10(24):2951-2963.
  • [1] 叶大铸 , 马寄晓 . 奥曲肽及其类似物用于肿瘤诊断的进展. 国际放射医学核医学杂志, 2003, 27(3): 97-100.
    [2] 陈礼林 , 谢丽君 , 张海波 , 杨洪文 , 何蕊 , 冯成涛 , 朱高红 . 靶向肽结合131I-PAMAM(G5.0) 抑制甲状腺髓样癌细胞增殖的研究. 国际放射医学核医学杂志, 2017, 41(5): 307-313. doi: 10.3760/cma.j.issn.1673-4114.2017.05.001
    [3] 王叙馥 . 放射性核素标记奥曲肽诊断小细胞肺癌的研究进展. 国际放射医学核医学杂志, 2003, 27(1): 11-13.
    [4] 姜磊 . 嗜铬细胞瘤的放射性核素诊断和治疗. 国际放射医学核医学杂志, 2008, 32(5): 278-281.
    [5] 张紫薇 , 程刚 . 放射性核素在嗜铬细胞瘤诊断与治疗中的应用进展. 国际放射医学核医学杂志, 2019, 43(1): 82-87. doi: 10.3760/cma.j.issn.1673-4114.2019.01.014
    [6] 谢君伟 , 左庆国 , 王都 . 多层螺旋CT与MRI在嗜铬细胞瘤诊断中的价值. 国际放射医学核医学杂志, 2011, 35(4): 245-248. doi: 10.3760/cma.j.issn.1673-4114.2011.04.013
    [7] 段炼 , 李险峰 . 甲状腺相关眼病与生长抑素受体显像. 国际放射医学核医学杂志, 2005, 29(3): 108-111.
    [8] 张渊琪 , 赵德善 . 分化型甲状腺癌的治疗进展. 国际放射医学核医学杂志, 2017, 41(2): 126-131. doi: 10.3760/cma.j.issn.1673-4114.2017.02.009
    [9] 李娇 , 韩娜 , 李凤岐 , 卢承慧 , 杨雪 , 林岩松 , 王叙馥 . 肺转移性分化型甲状腺癌术后131I治疗疗效及其影响因素的分析. 国际放射医学核医学杂志, 2022, 46(7): 405-411. doi: 10.3760/cma.j.cn121381-202203031-00204
    [10] 孔维静 , 徐颖 . 综合干预措施下评估首次131I清甲治疗对分化型甲状腺癌患者唾液腺的慢性损伤. 国际放射医学核医学杂志, 2018, 42(1): 30-35. doi: 10.3760/cma.j.issn.1673-4114.2018.01.006
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  1074
  • HTML全文浏览量:  77
  • PDF下载量:  2
出版历程
  • 收稿日期:  2005-01-15

奥曲肽及其类似物用于肿瘤治疗的进展

  • 1. 上海交通大学附属第六人民医院核医学科;
  • 2. Memorial Sloan-Kettering Cancer Center; New York 10021; USA
  • 收稿日期: 2005-01-15

摘要: 简单综述90Y-奥曲肽、177Lu-奥曲肽在肿瘤治疗中的应用价值。对奥曲肽治疗的原理、在肿瘤及正常组织中的分布、对肾脏功能的影响和保护剂的应用进行介绍,主要治疗的病种包括不摄取131I的分化型甲状腺癌转移灶、Hurthle细胞甲状腺癌、甲状腺髓样癌、来自胃肠胰的神经内分泌肿瘤、小细胞癌、嗜铬细胞瘤等。对应用适合的剂量和未来新的可能用于临床治疗的放射肽和发展方向加以综述。

English Abstract

    全文HTML

参考文献 (35)

目录

    /

    返回文章
    返回

    版权所有©中华医学会   备案号：津ICP备15006720号-3

    地址：天津市南开区白堤路238号电话：86-22-58089989
    86-22-85682389    传真：022-87890607

    本系统由 北京仁和汇智信息技术有限公司 开发 技术支持： info@rhhz.net